HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Fujian Provincial Cancer Hospital

Status

Enrolling

Conditions

Thyroid Cancer

Health Related Quality of Life

Tyrosine Kinase Inhibitor

Treatments

Drug: Tyrosine kinase inhibitor drugs.

Study type

Observational

Funder types

Other

Identifiers

NCT05824312

FJCH_HNS_QOL01

Details and patient eligibility

About

The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).

Full description

Surgical resection is the cornerstone of treatment for thyroid cancer. However, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. Another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. Tyrosine kinase inhibitors (TKI) have been proved to be effective in thyroid cancer patients. However, it was still unclear whether TKI drugs had influence on the HRQOL of LATC patients. The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, and EORTC THY 47 before surgery, and 1,3,6 and 12 months after treatment.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients age (18-70 year old)
Diagnosis of locally advanced thyroid cancer
Patient receiving TKI drugs.

Exclusion criteria

pregnancy or breastfeeding women;
history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.